Diagnostic Work-Up and Initial Management
This clinical presentation strongly suggests multiple myeloma, and you should immediately initiate a comprehensive diagnostic work-up while simultaneously managing the hypercalcemia and renal dysfunction as medical emergencies.
Immediate Diagnostic Work-Up
The constellation of hypercalcemia, renal dysfunction, macrocytic anemia, thrombocytopenia, lymphopenia, elevated total protein with low albumin represents classic CRAB criteria (Calcium elevation, Renal dysfunction, Anemia, Bone disease) highly suggestive of multiple myeloma 1, 2, 3.
Essential Laboratory Tests
Serum studies you must obtain immediately include 1, 2:
- Serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (SIFE) to detect and characterize M-protein
- Quantitative immunoglobulins (IgG, IgA, IgM) - the elevated total protein with low albumin suggests monoclonal protein
- Serum free light chain (FLC) assay with ratio - essential for diagnosis and required for complete response assessment
- Beta-2 microglobulin and LDH - reflect tumor burden and have prognostic significance
- Ionized calcium - critical because pseudohypercalcemia can occur with monoclonal proteins 4
- 24-hour urine collection for total protein
- Urine protein electrophoresis (UPEP) and urine immunofixation electrophoresis (UIFE)
Bone Marrow Examination
Bone marrow aspiration and biopsy are mandatory 2, 3 to:
- Quantify plasma cell infiltration (≥10% clonal plasma cells required for myeloma diagnosis)
- Perform cytogenetics and FISH studies for prognostic markers including del(17p), t(4;14), and t(14;16) 5
- Assess for other causes of cytopenias
Imaging Studies
Complete skeletal survey (skull, spine, pelvis, long bones) is the standard initial imaging 2, 6, 5. Consider whole-body MRI or PET-CT if available, particularly if skeletal survey is negative but clinical suspicion remains high 3.
Urgent Initial Management
Hypercalcemia Management - HIGHEST PRIORITY
Immediately initiate IV bisphosphonate (zoledronic acid or pamidronate) or denosumab 7. The 2023 Endocrine Society guidelines recommend treatment with IV bisphosphonate or denosumab for hypercalcemia of malignancy, with denosumab slightly preferred over bisphosphonates 7.
If severe hypercalcemia (>14 mg/dL or 3.5 mmol/L), add calcitonin to the IV bisphosphonate or denosumab for the first 48-72 hours only due to tachyphylaxis 7.
Aggressive IV hydration is essential 1, 8:
- Maintain hydration to protect renal function
- Loop diuretics may be needed if renal insufficiency or heart failure develops
- Avoid NSAIDs and IV contrast 1
Renal Dysfunction Management
Hydration is paramount to prevent further renal deterioration 1. Consider plasmapheresis (category 2B evidence) for severe renal dysfunction, particularly if light chain cast nephropathy is suspected 1. Renal dysfunction is NOT a contraindication to future transplant 1.
Supportive Care Considerations
- Monitor for infection risk - these patients are immunocompromised
- Thrombosis prophylaxis will be needed once immunomodulator therapy begins (full-dose aspirin or therapeutic anticoagulation) 1
- Avoid nephrotoxic agents including NSAIDs and IV contrast 1
Diagnostic Pitfalls to Avoid
Critical caveat: While CRAB criteria strongly suggest myeloma, other conditions can mimic this presentation 9, 10. Chronic lymphocytic leukemia and lymphoma have been reported with identical CRAB features. However, given the elevated total protein with low albumin (suggesting monoclonal protein), myeloma remains the most likely diagnosis.
Pseudohypercalcemia warning: Always measure ionized calcium in patients with monoclonal proteins 4. Calcium can bind to paraproteins, causing falsely elevated total calcium while ionized calcium remains normal. This could lead to misdiagnosis of smoldering versus active myeloma.
Do not delay treatment while awaiting complete diagnostic work-up if hypercalcemia is severe or symptomatic. The hypercalcemia and renal dysfunction require immediate intervention to prevent irreversible organ damage and death 7, 8.
Treatment Initiation After Diagnosis
Once myeloma is confirmed, treatment should begin immediately as this patient has symptomatic disease meeting CRAB criteria 3. The specific anti-myeloma regimen will depend on transplant eligibility (age, comorbidities, performance status), but triplet regimens are standard for both transplant-eligible and non-transplant candidates 11.
For transplant candidates: bortezomib-based triplet regimens are preferred 2, 12, 11
For non-transplant candidates: melphalan/prednisone/bortezomib (VMP) or melphalan/prednisone/thalidomide (MPT) are evidence-based options 3
Bortezomib-based regimens are particularly valuable in renal failure and may help preserve renal function 2, 12. Subcutaneous administration is preferred over IV to reduce neuropathy risk 11.